Implementation of H.R.5376 - Inflation Reduction Act of 2022 and potential reforms involving the treatment of orphan drugs.
H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
H.R.5539 - ORPHAN Cures Act.
Issues related to about insurance coverage of specialty treatments.
H.R.830 - HELP Copays Act.
Duration: January 1, 2014
to
present
General Issues: Medicare/Medicaid , Health Issues , Trade (Domestic & Foreign) , Science/Technology , Budget/Appropriations , Copyright/Patent/Trademark , Taxation/Internal Revenue Code
Spending: about $2,240,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2014: House of Representatives, U.S. Senate, Vice President of the U.S., Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Darren Willcox Asst for Policy, Speaker Dennis Hastert
Admin Asst; Leg Dir; Leg Asst, Cong. Porter Goss
House Rules Comm Assoc, Subcomm Staff Dir.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $80,000. The report was filed on April 22.
Original Filing: 301575591.xml
Lobbying Issues
Implementation of H.R.5376 - Inflation Reduction Act of 2022 and potential reforms involving the treatment of orphan drugs.
H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
H.R.5539 - ORPHAN Cures Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to about insurance coverage of specialty treatments.
H.R.830 - HELP Copays Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2023
In Q4, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $80,000. The report was filed on Jan. 18.
Original Filing: 301529195.xml
Lobbying Issues
Implementation of H.R.5376 - Inflation Reduction Act of 2022 and potential reforms involving the treatment of orphan drugs.
H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to about insurance coverage of specialty treatments.
H.R.830 - HELP Copays Act.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2023
In Q3, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $80,000. The report was filed on Oct. 20, 2023.
Original Filing: 301511893.xml
Lobbying Issues
Implementation of H.R.5376 - Inflation Reduction Act of 2022 and potential reforms involving the treatment of orphan drugs.
H.R.5539 - ORPHAN Cures Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to about insurance coverage of specialty treatments.
H.R.830 - HELP Copays Act.
2nd Quarter, 2023
In Q2, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $80,000. The report was filed on July 20, 2023.
Original Filing: 301489619.xml
Lobbying Issues
Implementation of H.R.5376 - Inflation Reduction Act of 2022 and potential reforms involving the treatment of orphan drugs.
H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to about insurance coverage of specialty treatments.
H.R.830 - HELP Copays Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $80,000. The report was filed on April 20, 2023.
Original Filing: 301467240.xml
Lobbying Issues
Implementation of H.R.5376 - Inflation Reduction Act of 2022 and potential reforms involving the treatment of orphan drugs.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to about insurance coverage of specialty treatments.
H.R.830 - HELP Copays Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $80,000. The report was filed on Jan. 20, 2023.
Original Filing: 301436634.xml
Lobbying Issues
Implementation of H.R.5376 - Inflation Reduction Act of 2022.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.4348 - FDASLA Act of 2022 and H.R.7667 - Food and Drug Amendments of 2022.
H.R.4373 - Further Additional Continuing Appropriations and Extensions Act, 2023 as it relates to FDA policy riders.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2022
In Q3, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $80,000. The report was filed on Oct. 20, 2022.
Original Filing: 301413197.xml
Lobbying Issues
H.R.5376 - Inflation Reduction Act of 2022.
FY23 IPPS as it relates to access to rare disease therapies.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.4348: FDASLA Act of 2022 and H.R.7667: Food and Drug Amendments of 2022.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2022
In Q2, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $80,000. The report was filed on July 20, 2022.
Original Filing: 301390354.xml
Lobbying Issues
H.R.5376: Build Back Better Act including H.R.3: Elijah E. Cummings Lower Drug Costs Now Act, and H.R.19. Lower Costs, More Cures Act of 2021.
FY 23 IPPS rule as it relates to low volume rare disease therapies.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.4348: FDASLA Act of 2022 and H.R.7667: Food and Drug Amendments of 2022.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2022
In Q1, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $80,000. The report was filed on April 19, 2022.
Original Filing: 301363361.xml
Lobbying Issues
H.R.5376: Build Back Better Act including H.R.3: Elijah E. Cummings Lower Drug Costs Now Act, and H.R.19. Lower Costs, More Cures Act of 2021.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Reauthorization of the Prescription Drug User Fee Act and related issues.
H.R.2471: Consolidated Appropriations Act, 2022.
H.R.7007: COVID Supplemental Appropriations Act, 2022.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2021
In Q4, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $60,000. The report was filed on Jan. 20, 2022.
Original Filing: 301331676.xml
Lobbying Issues
H.R.5376: Build Back Better Act including H.R.3: Elijah E. Cummings Lower Drug Costs Now Act, and H.R.19. Lower Costs, More Cures Act of 2021.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2021
In Q3, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $60,000. The report was filed on Oct. 20, 2021.
Original Filing: 301310141.xml
Lobbying Issues
FY'22 Budget Reconciliation including H.R.3: Elijah E. Cummings Lower Drug Costs Now Act. And H.R.19. Lower Costs, More Cures Act of 2021.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2021
In Q2, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $60,000. The report was filed on July 20, 2021.
Original Filing: 301284028.xml
Lobbying Issues
Education around COVID-19 vaccines.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Issues related to COVID-19 vaccines and TRIPS at WTO.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R.3: Elijah E. Cummings Lower Drug Costs Now Act.
H.R.19: Lower Costs, More Cures Act of 2021.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S.1260: Endless Frontier Act
1st Quarter, 2021
In Q1, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $60,000. The report was filed on April 20, 2021.
Original Filing: 301266685.xml
Lobbying Issues
Education around COVID-19 vaccines.
H.R.1319: American Rescue Plan Act of 2021.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2020
In Q4, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $60,000. The report was filed on Jan. 20, 2021.
Original Filing: 301238610.xml
Lobbying Issues
Education around COVID-19 vaccines.
H.R.133: Consolidated Appropriations Act, 2021 as it relates to health extenders.
Education about the 340(b) program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.107: to sunset the limit on the maximum rebate amount for single source drugs.
H.R.4996: Helping MOMS Act of 2020.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2020
In Q3, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $60,000. The report was filed on Oct. 20, 2020.
Original Filing: 301222637.xml
Lobbying Issues
Education around COVID-19 vaccines.
Education about the 340(b) program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.107: to sunset the limit on the maximum rebate amount for single source drugs.
H.R.4996: Helping MOMS Act of 2020.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2020
In Q2, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $60,000. The report was filed on July 20, 2020.
Original Filing: 301201610.xml
Lobbying Issues
Education around COVID-19 vaccines.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2020
In Q1, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $60,000. The report was filed on April 20, 2020.
Original Filing: 301176689.xml
Lobbying Issues
H.R.107: to sunset the limit on maximum rebate amount for single source drugs.
H.R.3: Lower Drug Costs Now Act of 2019.
H.R.19: Lower Costs, More Cures Act of 2019.
Regulatory and legislative proposals in the Administrations Blueprint.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2019
In Q4, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $50,000. The report was filed on Jan. 21, 2020.
Original Filing: 301128863.xml
Lobbying Issues
H.R.107: to sunset the limit on maximum rebate amount for single source drugs.
H.R.3: Lower Drug Costs Now Act of 2019.
H.R.19: Lower Costs, More Cures Act of 2019.
Regulatory and legislative proposals in the Administrations Blueprint.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2019
In Q3, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $50,000. The report was filed on Oct. 21, 2019.
Original Filing: 301078382.xml
Lobbying Issues
H.R.107: to sunset the limit on maximum rebate amount for single source drugs.
H.R.3: Lower Drug Costs Now Act of 2019.
Regulatory and legislative proposals in the Administrations Blueprint.
H.R.2113: Prescription Drug STAR Act / H.R.2296: FAIR Drug Pricing Act.
FY 2020 Continuing Resolution.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about innovative contracting and value based payments.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2019
In Q2, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $50,000. The report was filed on July 22, 2019.
Original Filing: 301056768.xml
Lobbying Issues
H.R.107: to sunset the limit on maximum rebate amount for single source drugs.
Regulatory and legislative proposals in the Administrations Blueprint.
H.R.2113: Prescription Drug STAR Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about innovative contracting and value based payments.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2019
In Q1, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $50,000. The report was filed on April 22, 2019.
Original Filing: 301035113.xml
Lobbying Issues
H.R.107: to sunset the limit on maximum rebate amount for single source drugs.
Regulatory and legislative proposals in the Administrations Blueprint.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about innovative contracting and value based payments.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2018
In Q4, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $50,000. The report was filed on Jan. 22, 2019.
Original Filing: 301015899.xml
Lobbying Issues
H.R.6642: "to sunset the limit on maximum rebate amount for single source drugs".
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about innovative contracting and value based payments.
Education about the 340(b) drug discount program including the CMS 340(b) CMP Rule.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D donut hole provision.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2018
In Q3, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $50,000. The report was filed on Oct. 16, 2018.
Original Filing: 300985887.xml
Lobbying Issues
H.R.6642: "to sunset the limit on maximum rebate amount for single source drugs".
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about innovative contracting and value based payments.
Education about the 340(b) drug discount program including the CMS 340(b) CMP Rule.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D donut hole provision.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2018
In Q2, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $50,000. The report was filed on July 20, 2018.
Original Filing: 300975636.xml
Lobbying Issues
Education about innovative contracting and value based payments.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about innovative contracting and value based payments.
Education about the 340(b) drug discount program including the CMS 340(b) CMP Rule.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D donut hole provision.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2018
In Q1, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $50,000. The report was filed on April 19, 2018.
Original Filing: 300950266.xml
Lobbying Issues
H.R.1834: Cancer Care Payment Reform Act of 2017.
Education about innovative contracting and value based payments.
Synchronization and Nonadherence Correction (SYNC) Act.
H.R.849/H.J.Res 51: IPAB Repeal Act and Joint Resolution related to IPAB Repeal.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program including the CMS 340(b) CMP Rule.
CDC Recommendations about flu treatments.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D donut hole provision and IPAB repeal.
H.R.1625: Consolidated Appropriations Act, 2018.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2017
In Q4, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $50,000. The report was filed on Jan. 19, 2018.
Original Filing: 300929327.xml
Lobbying Issues
H.R.1834: Cancer Care Payment Reform Act of 2017.
Education about innovative contracting and value based payments.
Synchronization and Nonadherence Correction (SYNC) Act.
H.R.2550: Medicare Telehealth Parity Act of 2017.
H.R.849/H.J.Res 51: IPAB Repeal Act and Joint Resolution related to IPAB Repeal.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program including the CMS 340(b) CMP Rule.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2017
In Q3, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $50,000. The report was filed on Oct. 20, 2017.
Original Filing: 300915525.xml
Lobbying Issues
H.R.1834: Cancer Care Payment Reform Act of 2017.
Synchronization and Nonadherence Correction (SYNC) Act.
H.R.849/H.J.Res 51: IPAB Repeal Act and Joint Resolution related to IPAB Repeal.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program including the CMS 340(b) CMP Rule.
H.R.2430/S.934: FDA Reauthorization Act of 2017.
H.R.1628: American Health Care Act and Better Care Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2017
In Q2, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $50,000. The report was filed on July 20, 2017.
Original Filing: 300897239.xml
Lobbying Issues
H.R.1834: Cancer Care Payment Reform Act of 2017.
H.R.849/H.J.Res 51: IPAB Repeal Act and Joint Resolution related to IPAB Repeal.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program including the CMS 340(b) CMP Rule.
H.R.2430/S.934: FDA Reauthorization Act of 2017.
H.R.1628: American Health Care Act. Better Care Reconciliation Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2017
In Q1, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $50,000. The report was filed on April 21, 2017.
Original Filing: 300878593.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors.
Education about AMP and Medicaid Rebates.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about the 340(b) drug discount program including the CMS 340(b) CMP Rule.
SYNC Act.
H.R. 1628: American Health Care Act.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2016
In Q4, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $50,000. The report was filed on Jan. 18, 2017.
Original Filing: 300848348.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors.
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
March 2016 CMS proposed rule implementing a new Part B drug payment model.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 34: 21st Century Cures Act conference report.
Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2016
In Q3, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $50,000. The report was filed on Oct. 20, 2016.
Original Filing: 300834985.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors.
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
March 2016 CMS proposed rule implementing a new Part B drug payment model.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 6: 21st Century Cures Act.
Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2016
In Q2, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $50,000. The report was filed on July 19, 2016.
Original Filing: 300815101.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors.
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
March 2016 CMS proposed rule implementing a new Part B drug payment model.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 6: 21st Century Cures Act.
Education about the value of innovative new medicines.
H.R.5414: FDA Cross-Center Collaboration Act of 2016.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2016
In Q1, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $50,000. The report was filed on April 20, 2016.
Original Filing: 300803038.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors.
March 2016 CMS proposed rule implementing a new Part B drug payment model.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 6: 21st Century Cures Act.
H.R. 4292: Synchronization & Nonadherence Correction (SYNC) Act of 2015.
Education about the value of innovative new medicines.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2015
In Q4, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $30,000. The report was filed on Jan. 20, 2016.
Original Filing: 300783970.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 6: 21st Century Cures Act.
H.R. 3537: Synthetic Drug Control Act of 2015.
H.R. 1786: "James Zadroga 9/11 Health and Compensation Reauthorization Act" with respect to potential budgetary offsets.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 9: Innovation Act, including proposed changes to the Inter Partes Review (IPR) process at the Patent and Trademark Office (PTO).
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
P.L. 114-74, "Bipartisan Budget Act of 2015".
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Trans Pacific Partnership agreement, with respect to data exclusivity for biologics.
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2015
In Q3, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $30,000. The report was filed on Oct. 20, 2015.
Original Filing: 300763576.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 6: 21st Century Cures Act, including improvements to biomarker qualification process at FDA.
H.R. 2841: Fair Access for Safe and Timely (FAST) Generics Act of 2015.
H.R. 3284: Mary Jo Lawyer Spano Mesothelioma Patient Registry Act of 2015.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 9: Innovation Act, including proposed changes to the Inter Partes Review (IPR) process at the Patent and Trademark Office (PTO).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2015
In Q2, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $30,000. The report was filed on July 20, 2015.
Original Filing: 300743442.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 6: 21st Century Cures Act, including improvements to biomarker qualification process at FDA.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 9: Innovation Act, including proposed changes to the Inter Partes Review (IPR) process at the Patent and Trademark Office (PTO).
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2015
In Q1, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $30,000. The report was filed on April 17, 2015.
Original Filing: 300718812.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors.
H.R. 2: Medicare Access and CHIP Reauthorization Act of 2015.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Agencies Lobbied
U.S. House of Representatives
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
4th Quarter, 2014
In Q4, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $30,000. The report was filed on Jan. 19, 2015.
Original Filing: 300700305.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 5214: "To require HHS to provide recommendations for clinical data registries".
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 5771: Tax Increase Prevention Act of 2014.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2014
In Q3, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $30,000. The report was filed on Oct. 16, 2014.
Original Filing: 300684683.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about access to therapies for children at risk of developing RSV (Respiratory Syncytial Virus), specifically with respect to guidelines by the American Academy of Pediatrics (AAP).
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).H.R. 4299: Improving Regulatory Transparency for New Medical Therapies Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitored issues related to S. 2360/H.R. 4679: Stop Corporate Inversions Act of 2014 in the context of corporate acquisition activity.
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2014
In Q2, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $30,000. The report was filed on July 21, 2014.
Original Filing: 300668257.xml
Lobbying Issues
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about access to therapies for children at risk of developing RSV(Respiratory Syncytial Virus), specifically with respect to guidelines by the American Academy of Pediatrics (AAP).
Legislative efforts to help accelerate the discovery, development and delivery of promising new treatments to patients (21st Century Cures).
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Monitoring issues related to S. 2360, H.R. 4679: Stop Corporate Inversions Act of 2014 in the context of corporate acquisition activity.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2014
In Q1, W Strategies, LLC lobbied for AstraZeneca Pharmaceuticals LP , earning $30,000. The report was filed on April 14, 2014.
Original Filing: 300635668.xml
Lobbying Issues
H.R. 4302: Protecting Access to Medicare Act of 2014.
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program.CMS proposed rule affecting the Medicare Advantage and Medicare Prescription Drug Benefit (Part D) Programs, specifically as it relates to changes to the Part D programs, including coverage of therapeutic classes and non interference.
Educated staff about concerns with changes in the Part D prescription drug program, specifically as it relates to changes in cost sharing for low income beneficiaries.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Education about access to therapies for children at risk of developing RSV(Respiratory Syncytial Virus), specifically with respect to guidelines by the American Academy of Pediatrics (AAP).
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2014
W Strategies, LLC filed a lobbying registration on April 9, 2014 to represent AstraZeneca Pharmaceuticals LP, effective Jan. 1, 2014.
Original Filing: 300633885.xml
Issue(s) they said they’d lobby about: Access to therapies for pediatric patients at risk for RSV.
Protecting access to Medicare. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...